 Home > Active Ingredient News > Blood System > Winbond Health Methylprednisolone Sodium Succinate for Injection passed the consistency evaluation of generic drugs

Winbond Health Methylprednisolone Sodium Succinate for Injection passed the consistency evaluation of generic drugs

 Last Update: 2021-06-20
 Source: Internet
 Author: User

Tags

chromosome 4 disorders

methylprednisolone 40 mg

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On June 9th, Winbond Health announced that Winbond Pharmaceuticals, a wholly-owned subsidiary, has recently received the "Drug Supplementary Application Approval Notice" approved and issued by the National Medical Products Administration for injection of methylprednisolone sodium succinate.

Methylprednisolone sodium succinate for injection is a kind of freeze-dried powder of glucocorticoid drugs.

It has anti-allergic, anti-shock, immunosuppressive and other effects.

It was approved for import and listing in China in 1999
.
According meters within a larger version of the national hospital network data (including city public health hospital, county public hospitals, urban community hospitals, township hospitals) show that injection of methylprednisolone sodium succinate 2019, 2020 sales were approximately 2.
4 billion yuan and 1.
9 billion yuan
.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.